Physiologically‐based pharmacokinetic modelling to predict oprozomib CYP3A drug–drug interaction potential in patients with advanced malignancies-Reference-Cited by-同舟云学术

Physiologically‐based pharmacokinetic modelling to predict oprozomib CYP3A drug–drug interaction potential in patients with advanced malignancies

Published:2018-12-25 Issue:3 Volume:85 Page:530-539
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Ou Ying¹,Xu Yang²^ORCID,Gore Lia³,Harvey R. Donald⁴,Mita Alain⁵,Papadopoulos Kyriakos P.⁶,Wang Zhengping¹,Cutler Richard E.⁷,Pinchasik Dawn E.¹,Tsimberidou Apostolia M.⁸

Affiliation:

1. Amgen Inc. South San Francisco CA USA

2. Amgen Inc. Thousand Oaks CA USA

3. University of Colorado Anschutz Medical Campus Aurora CO USA

4. Winship Cancer Institute of Emory University Atlanta GA USA

5. Cedars‐Sinai Medical Center Los Angeles CA USA

6. South Texas Accelerated Research Therapeutics San Antonio TX USA

7. Onyx Pharmaceuticals, Inc., an Amgen subsidiary South San Francisco CA USA

8. University of Texas MD Anderson Cancer Center Houston TX USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.13817

Reference33 articles.

1. Amgen Inc.Carfilzomib (KYPROLIS) prescribing information.2017. Available athttp://pi.amgen.com/~/media/amgen/repositorysites/pi‐amgen‐com/kyprolis/kyprolis_pi.pdf(last accessed 12 January 2018).

2. Design and Synthesis of an Orally Bioavailable and Selective Peptide Epoxyketone Proteasome Inhibitor (PR-047)

3. A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma

4. Oprozomib, pomalidomide, and dexamethasone (OPomd) in patients (Pts) with relapsed and/or refractory multiple myeloma (RRMM): Initial results of a phase 1b study (NCT01999335);Shah J;Blood,2015

5. Oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma: initial results from the dose escalation portion of a phase 1b/2, multicenter, open‐label study [abstract];Hari PN;Blood,2014

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Effect of Inflammatory Bowel Disease and Irritable Bowel Syndrome on Pravastatin Oral Bioavailability: In vivo and in silico evaluation using bottom-up wbPBPK modeling;AAPS PharmSciTech;2024-04-11

2. A Reliable and Effective UPLC-MS/MS Method for the Determination of Oprozomib in Rat Plasma;Journal of Analytical Methods in Chemistry;2023-07-11

3. Evaluation of Concomitant Use of Anticancer Drugs and Herbal Products: From Interactions to Synergic Activity;Cancers;2022-10-23

4. Enhancing Atorvastatin In Vivo Oral Bioavailability in the Presence of Inflammatory Bowel Disease and Irritable Bowel Syndrome Using Supercritical Fluid Technology Guided by wbPBPK Modeling in Rat and Human;AAPS PharmSciTech;2022-05-18

5. Proteasome Inhibitors and Their Pharmacokinetics, Pharmacodynamics, and Metabolism;International Journal of Molecular Sciences;2021-10-27